Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_assertion type Assertion NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_head.
- NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_assertion description "[Therefore, in the evidence-based, annually updated AGO guidelines for breast cancer management, the German Working Group for Gynecological Oncology (AGO) has recommended both biomarkers as risk-group-classification markers for routine clinical decision making in node-negative breast cancer, next to established clinical and histomorphological factors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_provenance.
- NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_assertion evidence source_evidence_literature NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_provenance.
- NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_assertion SIO_000772 18429492 NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_provenance.
- NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_assertion wasDerivedFrom befree-20140225 NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_provenance.
- NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_assertion wasGeneratedBy ECO_0000203 NP712237.RA-PZO-ih5En2U3a9V92T8qLHPtdawheqFVT40AFE_YOw130_provenance.